TY - JOUR
T1 - Rationale and design of the PROMETCO study
T2 - A real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective
AU - Koopman, Miriam
AU - Pinto, Carmine
AU - Bodoky, György
AU - Garcia-Carbonero, Rocio
AU - Marti, Francisca Marti
AU - Bachet, Jean Baptiste
N1 - Funding Information:
This study is sponsored by Servier Affaires Médicales, France. M Koopman has acted as an advisory board member for Nordic Farma, Merck-Serono, Pierre Fabre and Servier and received scientific grants from Bayer, Bristol Myers Squibb, Merck, Roche and Servier. Carmine Pinto has received honoraria for acting as an advisory board member or speaker for Amgen, Astellas, AstraZeneca, Bayer, BMS, Janssen, Lilly, Merck-Serono, MSD, Novartis, Roche, Sanofi and Servier. G Bodoky has acted as an advisory board member or speaker for Roche, Bayer, Janssen, Novartis, Pfizer, BMS and Merck. R Garcia-Carbonero has provided scientific advice and/or received honoraria from AAA, Advanz Pharma, Amgen, Bayer, BMS, HMP, Ipsen, Lilly, Merck, Midatech Pharma, MSD, Novartis, PharmaMar, Pfizer, Roche and Sanofi and has received research support from Pfizer, BMS and MSD. F Marti Marti has received honoraria from Servier. J-B Bachet has received personal fees from Amgen, AstraZeneca, Bayer, Merck Serono, Pierre Fabre, Roche, Sanofi and Servier and non-financial support from Amgen, Merck Serono, Roche and Servier. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
©) questionnaire. Data are collected retrospectively and prospectively up to 18 months. As of 13 October 2021, 544 patients from 18 countries had been enrolled. To the authors' knowledge, PROMETCO is the first international, real-world study of the continuum of care of mCRC patients in this setting.
PY - 2022/4
Y1 - 2022/4
N2 - The PROMETCO study is collecting real-world data on metastatic colorectal cancer (mCRC) patients with two progressions. This international, prospective, longitudinal, observational cohort study is collecting data on mCRC patients with two disease progressions since diagnosis and receiving subsequent treatment. Objectives include overall survival, treatment patterns, effectiveness and safety and patient-reported outcomes using the EuroQol 5-level, 5-dimensional questionnaire, the Brief Fatigue Inventory and a modified version of the ACCEPTance by the Patients of their Treatment (ACCEPT
©) questionnaire. Data are collected retrospectively and prospectively up to 18 months. As of 13 October 2021, 544 patients from 18 countries had been enrolled. To the authors' knowledge, PROMETCO is the first international, real-world study of the continuum of care of mCRC patients in this setting.
Trial registration number: NCT03935763 (ClinicalTrials.gov).
AB - The PROMETCO study is collecting real-world data on metastatic colorectal cancer (mCRC) patients with two progressions. This international, prospective, longitudinal, observational cohort study is collecting data on mCRC patients with two disease progressions since diagnosis and receiving subsequent treatment. Objectives include overall survival, treatment patterns, effectiveness and safety and patient-reported outcomes using the EuroQol 5-level, 5-dimensional questionnaire, the Brief Fatigue Inventory and a modified version of the ACCEPTance by the Patients of their Treatment (ACCEPT
©) questionnaire. Data are collected retrospectively and prospectively up to 18 months. As of 13 October 2021, 544 patients from 18 countries had been enrolled. To the authors' knowledge, PROMETCO is the first international, real-world study of the continuum of care of mCRC patients in this setting.
Trial registration number: NCT03935763 (ClinicalTrials.gov).
KW - Continuum of care
KW - Metastatic colorectal cancer
KW - Patient-reported outcomes
KW - Real-world evidence
KW - Study design
KW - Survival
KW - Treatment patterns
KW - Prospective Studies
KW - Humans
KW - Continuity of Patient Care
KW - Colorectal Neoplasms/drug therapy
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Observational Studies as Topic
KW - Retrospective Studies
KW - Cohort Studies
UR - http://www.scopus.com/inward/record.url?scp=85127938762&partnerID=8YFLogxK
U2 - 10.2217/fon-2021-1333
DO - 10.2217/fon-2021-1333
M3 - Article
C2 - 35043682
AN - SCOPUS:85127938762
SN - 1479-6694
VL - 18
SP - 1313
EP - 1320
JO - Future Oncology
JF - Future Oncology
IS - 11
ER -